Vitrafy Life Sciences Limited (VFY.AX)
ASX · AUD · Technology · Software - Infrastructure
A$2.52 (+4.56%) as of
Key statistics
- Market cap
- 192.14M
- Forward P/E
- -9.57
- EPS (TTM)
- -0.2500
- Dividend yield
- 0.00%
- 52-week range
- 1.2800 – 4.6600
- Revenue (TTM)
- 209k
- Profit margin
- 0.00%
- Analyst target
- A$5.05
- Volume
- 43.65k
About Vitrafy Life Sciences Limited
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
- Sector
- Technology
- Industry
- Software - Infrastructure
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.